Medicinal uses of inorganic compounds - 1

Resonance 04/2006; 11(4):75-89. DOI: 10.1007/BF02835732


In this two part article, we describe some aspects of inorganic drugs that bridge the areas of inorganic chemistry and medicine.
In this first part, we describe the therapeutic potential of inorganic compounds as neurological, anticancer, antimicrobial,
antiulcer, antiviral, anti-inflammatory, cardio vascular and insulin-mimetic agents.

1 Follower
228 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ebselen, a seleno-organic compound showing glutathione peroxidase-like activity, is one of the promising synthetic antioxidants. In the present study, we investigated the antioxidant activities of ebselen using a 12-O-tetradecanoylphorbol-13-acetate (TPA)-treated mouse skin model. Double pretreatments of mouse skin with ebselen significantly inhibited TPA-induced formation of thiobarbituric acid-reacting substance, known as an overall oxidative damage biomarker, in mouse epidermis, suggesting that ebselen indeed acts as an antioxidant in mouse skin. The antioxidative effect of ebselen is attributed to its selective blockade of leukocyte infiltration and activation leading to attenuation of the H(2)O(2) level. In in vitro studies, ebselen inhibited TPA-induced superoxide generation in differentiated HL-60 cells and lipopolysaccharide-induced cyclooxygenase-2 protein expression in RAW 264.7 cells. In addition, we demonstrated for the first time that ebselen potentiated phase II enzyme activities, including NAD(P)H:(quinone-acceptor) oxidoreductase1 and glutathione S-transferase in cultured hepatocytes and in mouse skin. These results strongly suggest that ebselen, a multifunctional antioxidant, is a potential chemopreventive agent in inflammation-associated carcinogenesis.
    Journal of Biological Chemistry 02/2002; 277(4):2687-94. DOI:10.1074/jbc.M109641200 · 4.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An Erratum has been published for this article in Medicinal Research Reviews 2004;24:685–686. Small synthetic receptor-binding peptides are the agents of choice for diagnostic imaging and radiotherapy of cancers due to their favorable pharmacokinetics. Molecular modification techniques permit the synthesis of a variety of bioactive peptides with chelating groups, without compromising biological properties. Various techniques have been developed that allow efficient and site-specific labeling of peptides with clinically useful radionuclides such as 99mTc, 123I, 111In, and 18F. Among them, 99mTc is the radionuclide of choice because of its excellent chemical and imaging characteristics. Recently, many 99mTc-labeled peptides have proven to be useful imaging agents. Beside 99mTc-labeled peptides, several peptides radiolabeled with 111In and 123I have been prepared and characterized. In addition, 18F-labeled peptides hold clinical potential due to their ability to quantitatively detect and characterize a variety of human diseases using positron-emission tomography. The availability of this wide range of peptides labeled with different radionuclides offers multiple diagnostic and therapeutic applications. Various receptors are over-expressed in particular tumor types and peptides binding to these receptors can be used to visualize tumor lesions scintigraphically. Thus, radiolabeled peptides have potential use as carriers for the delivery of radionuclides to tumors, infarcts, and infected tissues for diagnostic imaging and radiotherapy. Many radiolabeled peptides are currently under investigation to determine their potential as imaging agents. These peptides are designed mainly for thrombus, tumor, and infection/inflammation imaging. This article presents recent developments in small synthetic peptides for imaging of thrombosis, tumors, and infection/inflammation. © 2004 Wiley Periodicals, Inc. Med Res Rev, 24, No. 3, 357–397, 2004
    Medicinal Research Reviews 07/2004; 24(3):357-97. DOI:10.1002/med.20002 · 8.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: For Abstract see ChemInform Abstract in Full Text.
    Chemical Reviews 04/2005; 104(12):6255-85. DOI:10.1021/cr0406559 · 46.57 Impact Factor
Show more